NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free RKDA Stock Alerts $1.97 -0.09 (-4.37%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.97▼$2.0750-Day Range$1.89▼$3.0752-Week Range$1.85▼$7.30Volume2,905 shsAverage Volume20,361 shsMarket Capitalization$2.68 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Arcadia Biosciences alerts: Email Address Arcadia Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside407.6% Upside$10.00 Price TargetShort InterestHealthy0.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.33Based on 2 Articles This WeekInsider TradingAcquiring Shares$1,442 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.91 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.69% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently increased by 10.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RKDA. Previous Next 0.9 News and Social Media Coverage News SentimentArcadia Biosciences has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Basic Materials companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for RKDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Arcadia Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,442.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 17.73% of the stock of Arcadia Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Arcadia Biosciences Stock (NASDAQ:RKDA)Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More RKDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RKDA Stock News HeadlinesApril 25, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces Date of First Quarter 2024 Financial Results and Business Highlights Conference CallApril 21, 2024 | americanbankingnews.comArcadia Biosciences (NASDAQ:RKDA) Coverage Initiated at StockNews.comApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | msn.comSNDL, Arcadia Biosciences among Consumer Staples moversApril 6, 2024 | markets.businessinsider.comBuy Rating on Arcadia Biosciences Fueled by Strategic Initiatives and Innovative Product LaunchesApril 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcadia Biosciences Amidst Growth and Strategic ShiftsApril 1, 2024 | sg.news.yahoo.comMicrosoft unbundles Teams and Office 365 for customers worldwideApril 1, 2024 | finance.yahoo.comArcadia Biosciences Full Year 2023 Earnings: Misses ExpectationsApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.April 1, 2024 | finance.yahoo.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comArcadia Biosciences, Inc. (RKDA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Arcadia Biosciences Inc Earnings CallMarch 28, 2024 | sfgate.comArcadia Biosciences: Q4 Earnings SnapshotMarch 28, 2024 | msn.comRKDA Stock Earnings: Arcadia Biosciences Beats EPS, Misses Revenue for Q4 2023March 28, 2024 | benzinga.comRecap: Arcadia Biosciences Q4 EarningsMarch 28, 2024 | businesswire.comArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2023 Financial Results and Business HighlightsMarch 23, 2024 | finance.yahoo.comArcadia Biosciences, Inc. (RKDA)March 14, 2024 | finance.yahoo.comArcadia Biosciences (RKDA) Announces Date of Fourth Quarter 2023 Financial Results and Business Highlights Conference CallFebruary 20, 2024 | finance.yahoo.comArcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide AvailabilityFebruary 20, 2024 | businesswire.comArcadia Biosciences (RKDA) Expands GoodWheat™ Mac & Cheese with Nationwide AvailabilityFebruary 16, 2024 | ca.finance.yahoo.comHYFM Sep 2024 1.000 callFebruary 14, 2024 | money.usnews.comArcadia Biosciences IncFebruary 13, 2024 | investing.comArcadia Biosciences Inc (RKDA)December 14, 2023 | markets.businessinsider.comBuy Rating for Arcadia Biosciences Based on Strategic Initiatives and Product Line ExpansionDecember 2, 2023 | uk.investing.comEarnings call: Arcadia Biosciences reports growth driven by GoodWheat and Zola, explores strategic alternativesDecember 2, 2023 | morningstar.comArcadia Biosciences Inc RKDANovember 28, 2023 | finance.yahoo.comZacks Industry Outlook Highlights Bunge, The Andersons and Arcadia BiosciencesSee More Headlines Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Agricultural production - crops Sub-IndustryN/A Current SymbolNASDAQ:RKDA CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees21Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+407.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($14.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-246.80% Pretax Margin-246.85% Return on Equity-81.56% Return on Assets-50.80% Debt Debt-to-Equity RatioN/A Current Ratio4.17 Quick Ratio3.63 Sales & Book Value Annual Sales$5.33 million Price / Sales0.50 Cash FlowN/A Price / Cash FlowN/A Book Value$11.44 per share Price / Book0.17Miscellaneous Outstanding Shares1,360,000Free Float1,336,000Market Cap$2.68 million OptionableNot Optionable Beta0.60 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Stanley E. Jacot Jr. (Age 53)President, CEO & Director Comp: $527.9kMr. Thomas J. Schaefer (Age 48)CFO & Corporate Secretary Mr. Tracy BakerSenior Vice President of Seamless Technical OperationsKey CompetitorsSenesTechNASDAQ:SNESBTC DigitalNASDAQ:METXReed'sNYSE:REEDTattooed ChefNASDAQ:TTCFBorealis FoodsNASDAQ:BRLSWView All CompetitorsInsidersThomas J SchaeferBought 700 shares on 2/1/2024Total: $1,442.00 ($2.06/share)Thomas J SchaeferBought 649 shares on 8/4/2023Total: $2,381.83 ($3.67/share)Stanley Jacot JrBought 5,000 shares on 5/30/2023Total: $21,550.00 ($4.31/share)View All Insider Transactions RKDA Stock Analysis - Frequently Asked Questions Should I buy or sell Arcadia Biosciences stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RKDA shares. View RKDA analyst ratings or view top-rated stocks. What is Arcadia Biosciences' stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for Arcadia Biosciences' shares. Their RKDA share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 407.6% from the stock's current price. View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts. How have RKDA shares performed in 2024? Arcadia Biosciences' stock was trading at $3.13 on January 1st, 2024. Since then, RKDA shares have decreased by 37.1% and is now trading at $1.97. View the best growth stocks for 2024 here. When is Arcadia Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our RKDA earnings forecast. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) announced its quarterly earnings data on Thursday, March, 28th. The basic materials company reported ($2.48) earnings per share for the quarter, topping the consensus estimate of ($2.68) by $0.20. The basic materials company had revenue of $1.17 million for the quarter, compared to the consensus estimate of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative trailing twelve-month return on equity of 81.56%. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO? 1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF). When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RKDA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
